Main reasons for withdrawal biological DMARDs
| Biological DMARD | n | All reasons | Continuos remission | Lack of efficacy or loss of response | AE/SAE | Lack of funding |
|---|---|---|---|---|---|---|
| n (% )* | n (% )* | n (%)* | n (%)* | n (% )* | ||
| Infliximab | 207 | 28 (13.5) | 0 | 11 (5.3) | 10 (4.8) | 7 (3.4) |
| Adalimumab | 253 | 64 (25.3) | 2 (0.8) | 25 (9.9) | 11 (4.3) | 26 (10.3) |
| Etanercept | 230 | 125 (54.3) | 74 (32.2) | 12 (5.2) | 8 (3.5) | 31 (13.5) |
| Certolizumab pegol | 47 | 12 (25.5) | 1 (2.1) | 1 (2.1) | 2 (4.3) | 8 (17.0) |
| Abatacept | 211 | 44 (20.9) | 0 | 17 (8.1) | 16 (7.6) | 11 (5.2) |
| Tocilizumab | 120 | 27 (22.5) | 1 (0.8) | 2 (1.7) | 6 (5.0) | 18 (15.0) |
| Rituximab | 330 | 20 (6.1) | 2 (0.6) | 9 (2.7) | 1 (0.3) | 8 (2.4) |
% relative to the total number of patients in the subgroup of drug.